Axon Seminar In Vitro Diagnostics Wednesday 12 September 2012

Bringing an in vitro diagnostic product to the market is challenging and complex. Rules at the EU and national level are constantly changing, while regulatory policy is developing to get to grips with new products. A robust and scientifically supported regulatory and legal strategy is therefore key to successful market access.

Speakers and their presentations:

Sabine Ohse, Head Medical Devices Certification at BSI Group Regulatory strategy for in vitro diagnostics in the EU

Henk Vietor, CEO at Skyline Diagnostics Company experience with regulatory issues and how to deal with them

Erik Vollebregt, Partner at Axon Lawyers IVD Capita Exotica

Carine van den Brink, Partner at Axon Lawyers Promotion and sale of IVDs in EU


Navigate through our knowledgebase

Related articles

Article

The new Blue Guide 2022 – not much new for devices and IVDs, but certainly more confusion

In short After approximately six years after the previous (2016) version of the Blue Guide the 2022 version finally ‘dropped’ on 29 June 2022 in the Official Journal edition C edition of…

Read more

Article

The new Blue Guide 2022 – not much new for devices and IVDs, but certainly more confusion

In short After approximately six years after the previous (2016) version of the Blue Guide the 2022 version finally ‘dropped’ on 29 June 2022 in the Official Journal edition C edition of that day. I will discuss new and amended headings and subjects in the Blue Guide 2022 compared to the 2016 version in a […]

Article

Managing the 2024 MDR danger zone – and outlines of a potential solution in MDCG 2022-11

We live in interesting times for medical devices in the Union – some have said we are headed for a cliff edge at the end of the grace period. I would personally…

Read more